Technical Analysis for ITCI - Intra-Cellular Therapies Inc.

Grade Last Price % Change Price Change
grade D 12.82 -4.47% -0.60
ITCI closed down 4.47 percent on Monday, March 18, 2019, on 1.2 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ITCI trend table...

Date Alert Name Type % Chg
Mar 18 Fell Below 20 DMA Bearish 0.00%
Mar 18 Fell Below 50 DMA Bearish 0.00%
Mar 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 18 Outside Day Range Expansion 0.00%
Mar 15 Pocket Pivot Bullish Swing Setup -4.47%
Mar 15 NR7 Range Contraction -4.47%
Mar 15 NR7-2 Range Contraction -4.47%
Mar 15 Up 3 Days in a Row Strength -4.47%
Mar 15 Up 4 Days in a Row Strength -4.47%
Mar 15 Up 5 Days in a Row Strength -4.47%

Older signals for ITCI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS). Its lead product candidate includes ITI-007, which is in various clinical trials for the treatment of exacerbated and residual schizophrenia; bipolar disorders; sleep deficits associated with neurologic and psychiatric disorders; behavioral disturbances associated with dementia, including Alzheimer's disease; sleep maintenance insomnia; major depressive disorders; and autism spectrum disorders, PTSD, and IED. The company also develops ITI-002 phosphodiesterase (PDE) 1 inhibitors, including ITI-214 program that is in Phase-I clinical trial for the treatment of cognitive dysfunction in schizophrenia, as well as in pre-clinical stage for the treatment of Parkinson's disease, cognitive impairment in Alzheimer's disease, and attention deficit/hyperactivity disorders; and ITI-002 internal program that is pre-clinical stage for cardiovascular and other diseases. In addition, it develops early stage drug development programs comprising ITI-012 casein kinase 1 inhibitors and ITI-009 gamma secretase activating protein inhibitors for Alzheimer's disease. Further, the company develops PDE2 and PDE9 targets for treating neurodegeneration and bioenergetic failure in various CNS diseases. It has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize the company's proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. The company is headquartered in New York, New York.
Medicine Biopharmaceutical Disorders Alzheimer's Disease Neuroscience Schizophrenia Drug Development Parkinson's Disease Dementia Psychiatry Psychiatric Diagnosis Treatment Of Parkinson's Disease Aging Associated Diseases Cognitive Disorders Human Diseases Major Depressive Disorders Bipolar Disorders Cardiovascular And Other Diseases Cognitive Dysfunction Cognitive Impairment Learning Disabilities
Is ITCI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.78
52 Week Low 10.21
Average Volume 332,645
200-Day Moving Average 17.2841
50-Day Moving Average 12.9182
20-Day Moving Average 13.234
10-Day Moving Average 12.98
Average True Range 0.6599
ADX 11.04
+DI 22.5887
-DI 23.8832
Chandelier Exit (Long, 3 ATRs ) 13.0203
Chandelier Exit (Short, 3 ATRs ) 14.0097
Upper Bollinger Band 14.0825
Lower Bollinger Band 12.3855
Percent B (%b) 0.26
BandWidth 12.823032
MACD Line 0.0027
MACD Signal Line 0.0389
MACD Histogram -0.0363
Fundamentals Value
Market Cap 556.7 Million
Num Shares 43.4 Million
EPS -2.36
Price-to-Earnings (P/E) Ratio -5.43
Price-to-Sales 2144.19
Price-to-Book 1.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.25
Resistance 3 (R3) 14.38 14.03 14.01
Resistance 2 (R2) 14.03 13.67 13.97 13.93
Resistance 1 (R1) 13.43 13.45 13.26 13.30 13.85
Pivot Point 13.08 13.08 13.00 13.02 13.08
Support 1 (S1) 12.48 12.72 12.31 12.35 11.79
Support 2 (S2) 12.13 12.50 12.07 11.71
Support 3 (S3) 11.53 12.13 11.63
Support 4 (S4) 11.40